BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wendling D. The gut in spondyloarthritis. Joint Bone Spine 2016;83:401-5. [DOI: 10.1016/j.jbspin.2016.02.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Campos JF, Resende GG, Barbosa AJA, de Carvalho SC, Lage JA, Cunha PFS, de Souza SCS, Ferrari MLA. Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis. Int J Rheum Dis 2022. [PMID: 35855677 DOI: 10.1111/1756-185X.14388] [Reference Citation Analysis]
2 Hecquet S, Totoson P, Martin H, Prati C, Wendling D, Demougeot C, Verhoeven F. Intestinal permeability in spondyloarthritis and rheumatoid arthritis: A systematic review of the literature. Semin Arthritis Rheum 2021;51:712-8. [PMID: 34139524 DOI: 10.1016/j.semarthrit.2021.04.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Wendling D, Prati C, Chouk M, Verhoeven F. Reactive Arthritis: Treatment Challenges and Future Perspectives. Curr Rheumatol Rep 2020;22. [DOI: 10.1007/s11926-020-00904-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
4 Silva JE, Mayordomo AC, Dave MN, Aguilera Merlo C, Eliçabe RJ, Di Genaro MS. Dendritic Cells of Mesenteric and Regional Lymph Nodes Contribute to Yersinia enterocolitica O:3-Induced Reactive Arthritis in TNFRp55-/- Mice. J Immunol 2020;204:1859-68. [PMID: 32122996 DOI: 10.4049/jimmunol.1901137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wendling D, Prati C, Chouk M, Verhoeven F. Effects of anti-IL-23 and anti-IL-17: The hidden side of spondyloarthritis polymorphism? Joint Bone Spine 2020;87:5-7. [DOI: 10.1016/j.jbspin.2019.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Berthelot J, Wendling D. Translocation of dead or alive bacteria from mucosa to joints and epiphyseal bone-marrow: facts and hypotheses. Joint Bone Spine 2020;87:31-6. [DOI: 10.1016/j.jbspin.2019.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
7 Long GH, Tatro AR, Oh YS, Reddy SR, Ananthakrishnan AN. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Adv Ther 2019;36:3079-95. [PMID: 31562607 DOI: 10.1007/s12325-019-01095-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
8 Wendling D, Guillot X, Prati C, Miceli-Richard C, Molto A, Lories R, Dougados M. Effect of Gut Involvement in Patients with High Probability of Early Spondyloarthritis: Data from the DESIR Cohort. J Rheumatol 2020;47:349-53. [PMID: 31154418 DOI: 10.3899/jrheum.181326] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Torgutalp M, Poddubnyy D. IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin Biol Ther 2019;19:631-41. [PMID: 30957574 DOI: 10.1080/14712598.2019.1605352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
10 Kontny E, Dmowska-Chalaba J. Spondyloarthritis patients with and without intestinal symptoms - searching for discriminating biomarkers. Cent Eur J Immunol 2019;44:414-22. [PMID: 32140054 DOI: 10.5114/ceji.2019.92802] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Wendling D, Verhoeven F, Prati C. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 2019;19:55-64. [DOI: 10.1080/14712598.2019.1554053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
12 Reinhardt A, Prinz I. Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis. Front Immunol 2018;9:885. [PMID: 29922283 DOI: 10.3389/fimmu.2018.00885] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
13 Wendling D, Sondag M, Verhoeven F, Vuitton L, Koch S, Prati C. Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report. Joint Bone Spine 2018;85:255-6. [DOI: 10.1016/j.jbspin.2017.01.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
14 de Winter JJ, van de Sande MG, Baerlecken N, Berg I, Ramonda R, van der Heijde D, van Gaalen FA, Witte T, Baeten DL. Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. Arthritis Res Ther 2018;20:38. [PMID: 29490705 DOI: 10.1186/s13075-018-1535-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
15 Wendling D, Prati C. Spondyloarthritis: An expanding cast of cellular actors. Joint Bone Spine 2018;85:1-3. [DOI: 10.1016/j.jbspin.2017.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Sondag M, Verhoeven F, Guillot X, Prati C, Briot C, Vuitton L, Koch S, Wendling D. “Paradoxical” arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease. Joint Bone Spine 2018;85:133-4. [DOI: 10.1016/j.jbspin.2017.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
17 Kontny E, Dmowska-Chalaba J, Kwiatkowska B, Maśliński W. Cytokines and integrins related to inflammation of joint and gut in patients with spondyloarthritis and inflammatory bowel disease. Reumatologia 2017;55:276-83. [PMID: 29491535 DOI: 10.5114/reum.2017.72624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Wendling D, Prati C. Spondyloarthritis: Harlequin or Chameleon? J Rheumatol 2017;44:1293-4. [DOI: 10.3899/jrheum.170452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Clavel G, Boissier M, Sigaux J, Semerano L. Developments with experimental and investigational drugs for axial spondyloarthritis. Expert Opinion on Investigational Drugs 2017;26:833-42. [DOI: 10.1080/13543784.2017.1337744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Wendling D, Verhoeven F, Prati C. Calprotectin and spondyloarthritis. Expert Review of Clinical Immunology 2017;13:295-6. [DOI: 10.1080/1744666x.2017.1285700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]